Gilead Sciences (NASDAQ: GILD)
Gilead Sciences Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Gilead Sciences Company Info
Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands about 75% of the U.S. treatment market and more than 50% worldwide.
News & Analysis
Gilead Sciences Tops Estimates in Q3
Gilead Sciences posted robust revenue and EPS growth, exceeding expectations, and management raised full-year guidance.
Why Gilead Sciences Stock Thrashed the Market Today
In drug development, solid performance in large-scale clinical trials is crucial.
Gilead Posts Solid Revenue in Q2
Gilead Sciences cites strong growth in its HIV and oncology portfolios during Q2 2024.
3 Stocks With Mouthwatering Dividends You Can Buy Right Now
These stocks offer great dividends and more.
History Says the Nasdaq Will Keep Soaring in 2024 -- and Wall Street Thinks This High-Yield Dividend Stock Could Jump Nearly 20%
This biotech stock could be poised for a nice rebound if analysts are right.
Why Gilead Sciences Stock Dropped Today
Gilead missed revenue estimates with its latest quarter and issued underwhelming 2024 guidance.
2 Beaten-Down Dividend Stocks to Buy Hand Over Fist
These stocks aren't value traps.
Why Gilead Sciences Stock Got Mashed on Monday
A late-stage trial of an otherwise successful cancer drug failed to produce the desired results.
Valuation
Podcast Episodes
What Happened With CAR-T Stocks in 2018
Here’s how CAR-T therapies did in their first full year on the market.
Should You Stick With Gilead Sciences?
Declining sales increase the stakes for Gilead's most-promising R&D projects.
Celgene vs. Gilead Sciences: Who Reported Better Earnings?
Celgene's and Gilead Sciences’ Q2 2017 results are fueling gains in their stock prices, but is one of these stocks doing better than the other?
INDUSTRY FOCUS // Healthcare // 02-08-2017
We’re pitting off gene sequencing giant Illumina against giant biotech Gilead Sciences to see which company is the better buy for long-term investors.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.